关于股东股份部分解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 沧州明珠塑料股份有限公司（以下简称"本公司"）2026年2月10日接到前控 股股东河北沧州东塑集团股份有限公司（以下简称"东塑集团"）函告，获悉东 塑集团所持有的本公司股份部分解除质押，具体事项如下： 一、股东股份解除质押的基本情况 证券代码：002108 证券简称：沧州明珠 公告编号：2026-004 沧州明珠塑料股份有限公司 截至本公告披露日，东塑集团及其一致行动人所持公司股份质押情况如下： | 股东名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 解除质押 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一致行动人 | （股） | 比例 | 比例 | | | 原因 | | | 东塑集团 | 是 | 91，200,000 | 29.05% | 5.53% | 2025 年 1 月 22 日 | 202 ...

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

格隆汇2月9日丨沧州明珠(002108.SZ)公布，本次协议转让已过户完成，广州轻工通过直接持股联合表 决权委托的方式获得上市公司19.78%股份表决权，成为公司新的控股股东，广州市国资委成为公司实 际控制人。 ...

证券代码：002108 证券简称：沧州明珠 公告编号：2026-003 沧州明珠塑料股份有限公司 关于股东协议转让股份完成过户登记暨公司控制权发生变更的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 沧州明珠塑料股份有限公司（以下简称"公司"或"沧州明珠"） 于 2026 年2月9日收到公司股东河北沧州东塑集团股份有限公司（以下简称"东塑集团"） 的通知，获悉其协议转让公司股份事宜已完成过户登记手续。具体情况如下： 一、本次交易的基本情况 东塑集团及其一致行动人于立辉先生、赵明先生、原公司实际控制人于桂亭 先生与广州轻工工贸集团有限公司（以下简称"广州轻工"）于 2025 年 12 月 15 日在广州市签署了关于股份转让及表决权委托协议，东塑集团、于桂亭先生、 于立辉先生和赵明先生分别出具了《不谋求控制权承诺函》。广州轻工以协议转 让方式受让东塑集团持有的公司 166,539,465 股股份，该部分股份为无限售条件 流通股，转让股份数量占协议签署日公司总股本的 10.10%，同时东塑集团及其 一致行动人将持有的公司剩余 159,609,160 股 ...

沧州明珠公告，广州轻工以协议转让方式受让东塑集团持有的公司1.67亿股股份，占协议签署日公司总 股本的10.10%。同时，东塑集团及其一致行动人将持有的公司剩余1.6亿股股份（占协议签署日公司总 股本的9.68%）对应的表决权委托给广州轻工。广州轻工通过直接持股联合表决权委托的方式获得上市 公司19.78%股份表决权，成为公司新的控股股东。 ...

Group 1 - The core viewpoint of the article highlights a decline in China's plastic products production, with a reported decrease of 3.5% year-on-year in December 2025, totaling 759 million tons [1] - Cumulative production of plastic products in China for the entire year of 2025 reached 7,919.9 million tons, reflecting a slight decline of 0.2% compared to the previous year [1] - The article references a market analysis report by Zhiyan Consulting, which provides insights into the plastic products industry in China from 2026 to 2032, including investment scale forecasts [1] Group 2 - Listed companies mentioned include Guoen Co., Ltd. (002768), Jinfat Technology (600143), Fosl Plastic Technology (000973), Cangzhou Mingzhu (002108), Yongxin Co., Ltd. (002014), Wangzi New Materials (002735), Honghe Technology (603256), Daoming Optical (002632), Yuxing Co., Ltd. (300305), and Yinxin Technology (300221) [1] - The data source for the production statistics is the National Bureau of Statistics, with the analysis compiled by Zhiyan Consulting [1]

Group 1 - The plastic sector experienced a decline of 2.0% on January 29, with Ping An Electric leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] - Notable gainers in the plastic sector included Wanlangwei Plastic, which rose by 7.52% to a closing price of 45.20, and SDIC, which increased by 6.72% to 52.38 [1] Group 2 - The main funds in the plastic sector saw a net outflow of 401 million yuan, while retail investors had a net inflow of 500 million yuan [2] - Key stocks with significant fund flows included Shenjian Co., which had a net inflow of 24.3 million yuan from main funds, and SDIC, which saw a net outflow of 62.86 million yuan from speculative funds [3] - The overall trading volume for the plastic sector was substantial, with SDIC recording a trading volume of 476,200 shares and a transaction value of 2.494 billion yuan [1][2]

Group 1 - The company announced that it has signed a share transfer agreement with Dongsu Group and Guangzhou Light Industry Group, but the completion of the transaction is subject to regulatory approvals and remains uncertain [2] - The company will continue to monitor the progress of the share transfer and will disclose updates in a timely manner [2] - The company reported that its sales of lithium-ion battery separator products reached approximately 420 million square meters in the first three quarters of 2025 [2] Group 2 - The lithium-ion battery separator products produced by the company are applicable in various sectors, including new energy vehicle batteries, 3C lithium-ion batteries, electric two-wheelers, energy storage, and household appliances [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002108 证券简称：沧州明珠 公告编号：2026-002 上述募集资金到位情况业经中喜会计师事务所（特殊普通合伙）出具"中喜验资2022Y00082号"《验资 报告》予以验证。 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者的合法利益，根据《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第1号一主板上市公司规范运作》和《上市公司募集资金监管规 则》等法律、法规和规范性文件的要求，以及公司《募集资金管理制度》的规定，公司对募集资金实行 专户存储制度，并与开户银行、保荐机构、子公司分别签订了《募集资金三方监管协议》和《募集资金 四方监管协议》，公司募集资金专项账户仅用于公司募集资金的存储和使用，不用作其他用途。 三、本次注销募集资金专项账户的情况 2025年12月29日公司召开的第九届董事会第七次（临时）会议以及2026年1月14日召开的2026年第一次 临时股东会，审议通过了《关于募投项目结项并将节余募集资金永久补充流动资金的议案》，同意公司 将募投项目进行结项，并将节余募集资金永久补充流动资金，在募集资金 ...

Core Viewpoint - Cangzhou Mingzhu announced the transfer of all remaining funds from its fundraising special account to its general fund account for permanent working capital supplementation [1] Group 1: Fund Transfer Details - As of the announcement date, the total balance and interest of the fundraising special account amounted to 145.9674 million yuan, which includes 72.9252 million yuan of surplus funds and 73.0422 million yuan of unpaid contract payments and warranty funds [1] - The company has completed the procedures for the cancellation of the fundraising special account and terminated the corresponding storage supervision agreement with the bank and sponsor [1]